Clinicopathological and prognostic value of SIRT6 in patients with solid tumors: a meta-analysis and TCGA data review

作者：Xiaojing Wu, Shuyuan Wang, Xuanzhu Zhao, Sizhen Lai, Zhen Yuan, Yixiang Zhan, Kemin Ni, Zhaoce Liu, Lina Liu, Ran Xin, Xingyu Zhou, Xin Yin, Xinyu Liu, Xipeng Zhang, Wei Cui, Chunze Zhang · 发表于：Cancer Cell International · 年份：2022 · DOI：10.1186/s12935-022-02511-3 · 被引用次数：21 · 研究领域：Sirtuins and Resveratrol in Medicine、PARP inhibition in cancer therapy、Endoplasmic Reticulum Stress and Disease

PURPOSES: )-dependent class III deacylase sirtuin family, serves a variety of roles in the body's immune system. In this study, we sought to determine the relationship between the expression of SIRT6 and the clinicopathological outcomes of patients with solid tumours by conducting a meta-analysis of the available data. METHODS: The databases PubMed and ISI Web of Science were searched for relevant literature, and the results were presented here. Using Stata16.0, a meta-analysis was conducted to determine the impact of SIRT6 on clinicopathological characteristics and prognosis in malignancy patients. The results were published in the journal Cancer Research. The dataset from the Cancer Genome Atlas (TCGA) was used to investigate the prognostic significance of SIRT6 in various types of tumors. RESULTS: The inclusion and exclusion criteria were met by 15 studies. In patients with solid tumours, reduced SIRT6 expression was found to be related with improved overall survival (OS) (HR = 0.66, 95% CI = 0.45-0.97, P < 0.001) as well as improved disease-free survival (DFS) (HR = 0.48, 95% CI = 0.26-0.91, P < 0.001). Low SIRT6 expression was found to be associated with a better OS in breast cancer (HR = 0.49, 95% CI = 0.27-0.89, P = 0.179), but was found to be associated with a worse OS in gastrointestinal cancer (gastric cancer and colon cancer) (HR = 1.83, 95% CI = 1.20-2.79, P = 0.939) after subgroup analysis. In terms of clinicopathological characteristics, SIRT6 expression was fou...